Posted by Michael Wonder on 30 Nov 2019
Revised risperidone PBS listings for behavioural and psychological symptoms of dementia from 1 January 2020
29 November 2019 - Commencing 1 January 2020, the Pharmaceutical Benefits Scheme listings for risperidone for the treatment of behavioural and psychological symptoms of dementia of the Alzheimer type will change.
This change involves the addition of a new ‘continuing’ listing that is Authority Required (Telephone).
This listing will allow prescribers to treat patients with behavioural and psychological symptoms of dementia with risperidone, beyond 12 weeks of ‘initial’ therapy, when appropriate.
